87394-65-8

Basic information

• Product Name: 1-(5-CHLORO-PYRIDIN-2-YL)-PIPERAZINE
• Synonyms: CHEMBRDG-BB 4004469;5-CHLORO-2-(PIPERAZIN-1-YL)PYRIDINE;1-(5-CHLORO-PYRIDIN-2-YL)-PIPERAZINE;1-(5-CHLORO-2-PYRIDINYL)PIPERAZINE;1-(5-chloropyridin-2-yl)piperazine(SALTDATA: FREE);Piperazine, 1-(5-chloro-2-pyridinyl)-;1-(5-Chloro-2-pyridinyl)-piperazine 2HCl
• CAS NO: 87394-65-8
• Molecular Formula: C₉H₁₂ClN₃
• Molecular Weight: 197.66
• Product Categories: pharmacetical;Building Blocks;Pyridine
• Mol File: 87394-65-8.mol

Chemical Properties

• Boiling Point: 351.5°C at 760 mmHg
• Flash Point: 166.4°C
• Appearance: /
• Density: 1.213g/cm³
• Vapor Pressure: 4.08E-05mmHg at 25°C
• Refractive Index: 1.561
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 1-(5-CHLORO-PYRIDIN-2-YL)-PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(5-CHLORO-PYRIDIN-2-YL)-PIPERAZINE(87394-65-8)
• EPA Substance Registry System: 1-(5-CHLORO-PYRIDIN-2-YL)-PIPERAZINE(87394-65-8)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• Hazardous Substances Data: 87394-65-8(Hazardous Substances Data)

Usage

Uses

1-(5-Chloropyridin-2-yl)piperazine

InChI:InChI=1/C9H12ClN3/c10-8-1-2-9(12-7-8)13-5-3-11-4-6-13/h1-2,7,11H,3-6H2

Upstream product

• 110-85-0 piperazine 
• 16110-09-1 2,5 dichloropyridine 
• 87412-10-0 5-chloro-2-<<(trifluoromethyl)sulfonyl>oxy>pyridine 
• 40473-01-6 2-Bromo-5-chloro-pyridine 
• 945422-86-6 tert-butyl 4-(5-chloropyridin-2-yl)piperazine-1-carboxylate 
• 4214-79-3 5-chloro-2-pyridinol 

Downstream Products

• 401566-32-3 C₂₂H₃₂N₅O₃SCl 
• 1219624-30-2 1-{2-[4-(5-chloropyridin-2-yl)piperazin-1-yl]-2-oxoethyl}-3,3-diphenylpyrrolidin-2-one 
• 223512-06-9 N-(4-((4-(5-Chloropyridin-2-yl)piperazin-1-yl)methyl)phenylmethyl)acetamide 

Relevant articles and documents

SYA 013 analogs as moderately selective sigma-2 (σ2) ligands: Structure-affinity relationship studies

Several lines of evidence suggest that selective sigma-2 (σ2) ligands might be useful for the treatment of solid tumors. However, very few selective σ2 ligands have been identified. This study was aimed at identifying new selective σ

GLYCINE COMPOUND

[Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that a compound of the present invention or a salt thereof exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. The present invention further relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound of the present invention or a salt thereof, and an excipient.

PICOLINAMIDE AND PYRIMIDINE-4-CARBOXAMIDE COMPOUNDS, PROCESS FOR PREPARING AND PHAMACEUTICAL COMPOSITION COMPRISING THE SAME

Provided are picolinamide and pyrimidine-4-carboxamide compounds, a method for preparing the same, a pharmaceutical composition containing the same, and a medical use using the compound as an agent for preventing, regulating, and treating diseases related to regulation of glucocorticoids by using selective inhibitory activity of the compound for an 11β-HSD1 enzyme. The picolinamide and pyrimidine-4-carboxamide compounds of the present invention are selective inhibitors of human-derived 11β-HSD1 enzymes, and are useful in an agent for preventing, regulating, and treating diseases related to glucocorticoid regulation in which human- derived 11β-HSD1 enzymes are involved, for example, metabolic syndromes such as, type 1 and type 2 diabetes, diabetes later complications, latent autoimmune diabetes adult (LAD A), insulin tolerance syndromes, obesity, impaired glucose tolerane (IGT), impaired fasting glucose (IFG), damaged glucose tolerance, dyslipidemia, atherosclerosis, hypertension, etc.

PIPERAZINES AND PIPERIDINES AS mGluR5 POTENTIATORS

The invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: wherein Ar1, Ar2, A, X, Y, m, n and R1 to R5 are described in the specification.

Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2- yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist

High throughput screening using the recombinant human TRPV1 receptor was used to identify a series of pyridinylpiperazine ureas (3) as TRPV1 vanilloid receptor ligands. Exploration of the structure-activity relationships by parallel synthesis identified t

Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents

Compounds of formula (I) useful as metalloproteinase inhibitors, especially as inhibitors of MMP 13.

Piperazine compounds and medicinal use thereof

The present invention relates to a piperazine compound of the formula wherein R1and R2are each hydrogen, halogen, lower alkyl, lower alkoxy, amino, substituted amino, nitro, hydroxy or cyano, R3, R4and R5are each hydrogen, halogen, lower alkyl, lower alkoxy, nitro, amino, substituted amino or hydroxy, R6and R7are each hydrogen, lower alkyl, lower alkyl substituted by halogen, aralkyl, acyl or lower acyl substituted by halogen, R8and R9are each hydrogen or lower alkyl, Y is lower alkylene and the like, and ring A is phenyl, pyrimidyl, thiazolyl, pyridyl, pyrazyl or imidazolyl, a pharmaceutically acceptable salt thereof and pharmaceutical agents containing these compounds. The compound of the present invention has superior TNF-α production inhibitory effect and/or IL-10 production promoting effect, and, since it is free of or shows only strikingly reduced expression of an effect on the central nervous system, the compound is useful as a highly safe and superior TNF-α production inhibitor an/or IL-10 production promoter and is useful as an agent for the prophylaxis or treatment of various diseases caused by abnormal TNF-α production, diseases curable with IL-10, such as chronic inflammatory diseases, acute inflammatory diseases, inflammatory diseases due to infection, autoimmune diseases, allergic diseases, and TNF-α mediated diseases.

IMIDAZO[1,2-A]PYRIDINES FOR THE TREATMENT OF CNS AND CARDIAC DISEASES

The present invention relates to imidazo[1,2-a]pyridine compounds of formula (1) STR1 which are dopamine D-4 antagonists and useful as anti-psychotic agents.

Pyrrolo-pyridine derivatives

A class of pyrrolo[2,3-b]pyridine derivatives, substituted at the 3-position by a substituted piperazinylmethyl moiety, are antagonists of dopamine receptor subtypes within the brain, having a selective affinity for the dopamine D 4 receptor subtype over other dopamine receptor subtypes, and are accordingly of benefit in the treatment and/or prevention of psychotic disorders such as schizophrenia while manifesting fewer side-effects than those associated with classical neuroleptic drugs.

Synthesis and anxiolytic activity of N-substituted cyclic imides (1R*,2S*3R*,4S*)-N-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,3-b icyclo[2.2.1]heptanedicarboxime (Tandospirone) and related compounds

A series of cyclic imides bearing a ω-(4-aryl and 4-heteroaryl-1-piperazinyl)alkyl moieties was synthesized and tested in vivo for anxiolytic activity. The in vitro binding affinities of these compounds were also examined for 5-HT(1A) receptor sites. Structure-activity relationships within these series are discussed. One of these compounds, (1R*,2S*,3R*,4S*)-N-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,3- bicyclo[2.2.1]heptanedicarboximide (1: tandospirone), was found to be equipotent with buspirone in its anxiolytic activity and more anxio-selective than buspirone and diazepam. Tandospirone (1) is currently undergoing clinical evaluation as a selective anxiolytic agent.